Spotlight Innovation

Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery

Retrieved on: 
Friday, December 1, 2023
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Intarsia, Initial public offering, Amylin Pharmaceuticals, GSK plc, Vancomycin, Senior, Head, Protein, APS, Artificial intelligence, Machine learning, Medication, Eli Lilly, Therapy, Perpetual, Eli Lilly and Company, MD, Harvard Medical School, Deep learning, Drug discovery, Drug development, Spotlight Innovation, Doctor of Philosophy, Incretin, Autoimmunity, Fine chemical, Management, Chemistry

Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.

Key Points: 
  • Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery.
  • “Perpetual Medicines is capitalizing on recent advances in computational modeling based on artificial intelligence, deep learning and machine learning that enable access for the first time to the enormous, untapped peptide chemical space for drug discovery,” said Dr. Blanchard.
  • This approach has the potential to accelerate peptide drug discovery, reduce cost, and increase the quality of drug candidates.
  • Ved Srivastava, PhD, Chief Technology Officer – Dr. Srivastava brings to Perpetual Medicines more than 25 years of experience in the discovery and development of peptide therapeutics.

Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, April 18, 2023
Pancreatic cancer, KRAS, AACR, Senior, CRC, DOR, DCR, DLT, Cancer, Trae tha Truth, Mutation, NSCLC, Lung cancer, PFS, ASCO, HKEX, Dor, Patient, Colorectal cancer, Anemia, Ophthalmology, Itch, Bilirubin, Weakness, CSCO, MTD, Hospital, Death, ORR, Autoimmunity, Safety, Pharmaceutical industry, Spotlight Innovation

Topic: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: updated results

Key Points: 
  • Topic: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: updated results
    IBI351(GFH925) is a novel, irreversible covalent inhibitor of KRASG12C mutation.
  • Favorable safety and tolerability and promising antitumor activity of IBI351 monotherapy were observed in previously-treated advanced NSCLC harboring KRASG12C mutation.
  • The update data shows the favorable safety and promising activity of IBI351 (GFH925) monotherapy in KRAS G12C mutated advanced NSCLC.
  • We are working to advance into late stage clinical development to explore the potential of IBI351 as monotherapy and in combo-therapy.

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Retrieved on: 
Monday, November 28, 2022
Autoimmune disease, Autoimmunity, Metastasis, Environment, CML, Medicine, Nature, NSCLC, Selpercatinib, Metabolic disorder, Hospital, Chemistry, CMC, Soochow University, TKI, Eli Lilly and Company, Mutation, First Affiliated Hospital of Xinjiang Medical University, Eli Lilly, Trial of the century, Ophthalmology, Peking Union Medical College, Ramucirumab, HKEX, Control, News, Tolerability, NDA, Efficacy, Cancer, Social conditions in Honduras, Integrity, Stock exchange, Main, MD Anderson Cancer Center, Sintilimab, Bevacizumab, The First Affiliated Hospital of Wenzhou Medical University, NMPA, Motherboard, Vaccine, Management, Pharmaceutical industry, Patient, Safety, Spotlight Innovation, Hematology, Incyte

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Retrieved on: 
Wednesday, August 24, 2022
Safety, Chemistry, Food and Drug Administration, Integrity, Toxicity, R & D, Interleukin 2, CD4, PD-1, Company, MD Anderson Cancer Center, Social conditions in Honduras, Patient, Cancer, Food, Senior, CMC, Sintilimab, Lymphoma, HKEX, Trial of the century, NDA, R, NMPA, Adalimumab, Immunotherapy, Stock exchange, News, Eli Lilly and Company, Marketing, Nature, Control, Ophthalmology, Motherboard, IND, HK, Autoimmunity, Bevacizumab, CD8, Eli Lilly, Innovation Academy Charter School, Clinical trial, Environment, Pharmaceutical industry, Vaccine, Fine chemical, Ramucirumab, Regulatory T cell, Spotlight Innovation, Incyte

Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.

Key Points: 
  • Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.
  • We are looking forward to the positive results of IBI363 in patients with advanced solid tumors or lymphoma.
  • IBI363 is our first molecule to initiate clinical study in Australia, which marks a solid step of Innovent's global innovation strategy.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Breakthrough Cooperation of Legend Capital's Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM

Retrieved on: 
Wednesday, June 15, 2022
Therapy, Culture, Global Vision, Belt and Road Initiative, CEO, Belt, Lists of countries and territories, Cancer, Technology transfer, Investment, Policy, Ovarian cancer, Partnership, Food, Philosophy, Patient, Business development, NSCLC, Bevacizumab, COVID, Islam, Fine chemical, Drug, Etana, Spotlight Innovation

Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.

Key Points: 
  • Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.
  • Nathan Tirtana, President Director of Etana, said, "Etana appreciates the support of BPOM for approving Bevagen for cancer patients in Indonesia.
  • By leveraging the advantages of the portfolio ecosystem, Legend Capital has played an active role in promoting the strategic cooperation between Innovent and Etana.
  • Mr. Frank Hong, Managing Director of Legend Capital, said, "Congratulations to Innovent and Etana for the approval of the first biosimilar in Indonesia.

Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, May 16, 2022
Efficacy, Control, NDA, Safety, Ophthalmology, Cancer, Eli Lilly and Company, Medicine, KRAS, News, Nature, Integrity, Marketing, American Society of Clinical Oncology, NSCLC, CMC, SAN, Housing and Building National Research Center, Social conditions in Honduras, Motherboard, Company, Autoimmunity, Sintilimab, Patient, Ruijin Hospital, FGFR2, Shanghai Jiao Tong University School of Medicine, ASCO, Eli Lilly, HKEX, MD Anderson Cancer Center, Translational medicine, TKI, TIK, Environment, PI3K, Bevacizumab, Society, Chemistry, BCL, Stock exchange, NMPA, State Key Laboratories, Pharmaceutical industry, Medical device, Generic drug, Spotlight Innovation, Incyte, Ramucirumab, Hematology

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.

Key Points: 
  • Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic, ophthalmologyand other major diseases.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Degenerative disease, Peking Union Medical College, Social conditions in Honduras, Autoimmunity, Chemistry, Environment, NMPA, Metabolism, Association, American Association for Cancer Research, Technology, Stock exchange, Medicine, NDA, Oncology, Trial of the century, ORR, CMC, American Association, HKEX, Bevacizumab, Anemia, Eli Lilly and Company, Department, MD Anderson Cancer Center, BCR, DCR, Immunotherapy, Death, Motherboard, AACR, Trae tha Truth, Integrity, Macrophage, SAN, FDA, PD-L1, Patient, ICI, Company, PR, IND, CD47, Cancer, NSCLC, PD-1, Hospital, Safety, News, Nature, Control, SCLC, Pharmaceutical industry, Spotlight Innovation, Fever, Ramucirumab, Incyte

This is a first-in-human, phase Ia/Ib dose escalation/expansion study of IBI322 monotherapy in patients with advanced solid tumors who failed standard of care treatment.

Key Points: 
  • This is a first-in-human, phase Ia/Ib dose escalation/expansion study of IBI322 monotherapy in patients with advanced solid tumors who failed standard of care treatment.
  • Treatment related adverse events (TRAEs) occurred in 74.1% (43/58) patients, most frequent TRAEs including anemia, platelet count decreased, pyrexia.
  • Phase Ia dose expansion study with IBI322 monotherapy has kept updating with longer follow-up after the cut-off date.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

CAR T Drug Pipeline Market Research Report 2022: Insights About 120+ Companies and 460+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 9, 2022
Health, Pharmaceutical, Molecule, Epithelial cell adhesion molecule, Multiple myeloma, NDA, News, TT11, CEA, Spotlight Innovation, Fragment crystallizable region, Liver cancer, Acquisition, Lymphoid leukemia, JW, Stomach cancer, Therapy, Clinical trial, CD8A, Technology, Patient, BCMA, Carcinoembryonic antigen, University, Review, CD19, DLBCL, Leukemia, Novartis, National Medical Products Administration, Immunotherapy, International, RRMM, Acute leukemia, Diffuse large B-cell lymphoma, NMPA, TNK, CAR, CD30, Cell, Discovery, Vaccine, Pharmaceutical industry

This report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in CAR-T pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in CAR-T pipeline landscape.
  • 'CAR-T - Pipeline Insight, 2022' outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the CAR-T pipeline landscape is provided which includes the disease overview and CAR-T treatment guidelines.
  • The assessment part of the report embraces, in depth CAR-T commercial assessment and clinical assessment of the pipeline products under development.

Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases

Retrieved on: 
Tuesday, January 18, 2022
Health, Infectious Diseases, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Research, Enzyme, Antibody, HKEX, Conformation, Therapy, Program, Platform, Protein engineering, Inflammation, Spotlight Innovation, Pharmaceutical industry

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, today announced a license option agreement with Innovent Biologics, Inc. (HKEX: 01801) (Innovent) for up to three enzyme specific inhibitors derived from Amagmas proprietary SEIZMIC Platform.

Key Points: 
  • Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, today announced a license option agreement with Innovent Biologics, Inc. (HKEX: 01801) (Innovent) for up to three enzyme specific inhibitors derived from Amagmas proprietary SEIZMIC Platform.
  • The collaboration will allow Innovent to access novel, first-in-class molecules for inflammatory disorders with little to no existing treatment options.
  • Amagma will secure clinical manufacturing for its lead programs and gain a proven regional partner with extensive expertise in protein engineering and manufacturing.
  • Amagma Therapeutics is developing precision antibody therapeutics against inflammatory diseases which have proven to be intractable by other approaches.

Sirnaomics Ltd. Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Sunday, December 19, 2021
Method, Global, RNA, RNA transfection, SEHK, Company, Motherboard, Board, Patent Cooperation Treaty, Teleport Communications Group, Toxicity, STP, IND, Stock exchange, Review, Survival, Vaccine, PNP, Escape Room, Liver, CEO, Research, Gene, Patient, Therapy, Tissue, China International Capital Corporation, Patent, Behzad Razavi, Hepatocyte, Eye, RNA interference, N-Acetylgalactosamine, Spotlight Innovation, GMP, Fibrosis, Sirna, Technology, Senior, Entrepreneurship, Property management, Pharmaceutical industry, Limited, TGF

HONG KONG, Dec 19, 2021 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics" or "Company", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company withs strong presence in both China and the U.S., today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").

Key Points: 
  • HONG KONG, Dec 19, 2021 - (ACN Newswire) - Sirnaomics Ltd. ("Sirnaomics" or "Company", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company withs strong presence in both China and the U.S., today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").
  • Dealings in shares on SEHK are expected to commence on December 30, 2021 (Thursday), with the stock code of 2257.HK in board lots of 50 shares each.
  • Sirnaomics is led by the management team with deep experience and capabilities in discovering, developing, manufacturing and commercializing RNA therapeutics.
  • This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Sirnaomics Ltd. For further information, please contact: